AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00000251 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 100% oxygen
Description: Placebo
Study NCT02863380 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional magnetic resonance imaging used to individualize rTMS protocol
Description: Procedure consisting in personalizing the rTMS targets and stimulation pattern based on functional magnetic resonance imaging
Study NCT02863380 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging used to individualize rTMS protocol
Description: Procedure consisting in personalizing the rTMS targets and stimulation pattern based on functional magnetic resonance imaging
Study NCT02863380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Individualized rTMS (transcranial magnetic stimulation)
Study NCT02863380 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Classical rTMS (transcranial magnetic stimulation)
Study NCT02863380 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Classical tDCS (transcranial direct current stimulation)
Study NCT02842424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: Ramipril therapy will start at 2.5mg/day for 1 week. Then 5mg/day for 1 week and will be increased to 10mg/day by the third week. The patients will stay on Ramipril 10mg/day for 22 weeks.
Study NCT02079155 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robot-assisted laparoscopic surgery
Description: Undergo RALP
Study NCT02079155 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted laparoscopic surgery
Description: Undergo R-LESS RP
Study NCT02079155 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02079155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02079155 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02079155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02079155 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02079155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT03244579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Adjusting the quantity and quality of food intake to improve glycemic control, maternal and newborn health outcomes of women with gestational diabetes.
Study NCT03983889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam is used as a common medication for sedation in all groups.
Study NCT03983889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.
Study NCT03983889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is used for sedation in bronchoscopy with less impact on respiration.
Study NCT03983889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil is used for analgesia to prevent bronchoscopy induced cough.
Study NCT03983889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol is used for sedation with high efficacy but more side effect on respiration than dexmedetomidine.
Study NCT05603520 — intervention group
Intervention type: OTHER
Intervention: Collection of Clinical Data
Description: prospectively and systematically collection of clinical research data from apparently healthy volunteers and patients with aortic stenosis and aneurysms
Study NCT01907282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Focused Treatment
Description: Treatment for family that focuses on skills for coping with subthreshold positive and negative symptoms and improving family communication and problem-solving
Study NCT01907282 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Care
Description: This 3-session psychoeducational treatment assists individuals and families in coping with early warning signs of psychotic episodes.
Study NCT01731782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Study NCT01731782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline placebo (for bupivacaine)
Description: Normal saline to mimic bupivacaine
Study NCT02298725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DGA Diet Plan
Description: A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with food group recommendations set in the 2010 Dietary Guidelines for Americans.
Study NCT02298725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NHANES Diet Plan
Description: A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with the NHANES What we eat in America report.
Study NCT02418091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Using Telehealth to slow progression of diabetic kidney disease automated population program identifies patients and engages them to optimize DKD medication adherence and health behaviors using 2-way communication via patient-selected technology (mobile/web-based applications, text messaging, interactive voice response, or e-mail) backed by case management via the phone for suboptimal control or health status. The STOP-DKDAutomated Population Program will deliver a tailored, multi-factorial intervention to address medication self-management and modify multiple risk factors simultaneously through a combination of patient self-monitoring, behavioral therapies and education that optimize adherence and self-efficacy.
Study NCT02499887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclamethasone dipropionate
Description: Inhaler
Study NCT04136639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Miswak
Description: sticks
Study NCT04136639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grape Seed Extract Mouthwash
Description: Mouthwash
Study NCT04136639 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fluoride
Description: mouthwash
Study NCT02499887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol
Description: Inhaler
Study NCT02499887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol
Description: Inhaler
Study NCT03751150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: The runners will be asked to perform the training program twice a week. The intervention consist of muscle control and foam rolling exercises for the lower extremities.
Study NCT04668391 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided anterior quadratus lumborum block at the lateral supra-arcuate ligament
Description: Bilateral single-injection 20 ml 0.56% ropivacaine. Intravenous analgesia was started postoperatively and consisted of 1ug/ml sufentanil，2 ml/h with a 5-minute lockout period, a limited 12 ml/h dose.
Study NCT04668391 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural analgesia
Description: A thoracic epidural at the level of T7-10. Epidural infusion was started postoperatively and consisted of sufentanil (0.6ug/mL) and ropivacaine（0.2%） at 3ml/h.
Study NCT02499887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Oral corticosteroid
Study NCT02499887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral corticosteroid
Study NCT06034626 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intense pulsed light
Description: Each MGD patient underwent three treatment sessions at three-week intervals and three follow-up examinations over the course of treatment.
Study NCT01436838 — intervention group
Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: All patients will be prescribed with Betaseron and be instructed on treatment by their phisicians
Study NCT06554262 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention was involved in this study
Study NCT00246012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intetumumab
Description: Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). In Phase 2, intetumumab (5 mg/kg or 10 mg/kg) will be administered for 8 cycles until no evidence of disease progression or unacceptable toxicity. If a participant responds to therapy with stable disease (SD) or better, the participant will be eligible to receive up to 8 cycles of extended administrations.
Study NCT06034626 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intense pulsed light
Description: Each MGD patient underwent three treatment sessions at three-week intervals and three follow-up examinations over the course of treatment.
Study NCT06034626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3% hyaluronic acid eye drops
Description: 0.3% hyaluronic acid eye drops (Hialid; Santen, Osaka, Japan) four times a day during the study, including the follow-up period.
Study NCT06034626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% hyaluronic acid eye drops
Description: 0.3% hyaluronic acid eye drops (Hialid; Santen, Osaka, Japan) four times a day during the study, including the follow-up period.
Study NCT01693367 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DLS 5.0 (Dynamic locking screws)
Description: Open reduction and internal fixation (ORIF) of the distal femur with a large fragment locking plate (LISS, LCP) and DLS 5.0
Study NCT02136121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: da Vinci Sp Surgical System - Robotic
Description: robotic assisted laparoscopic single-port system
Study NCT02530606 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photoacoustic Imaging
Description: Undergo PAI
Study NCT03910998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery
Description: Bolus of rocuronium 0.1 mg/kg at the discretion of anesthetist to keep the TOF between 1-3 out of 4 during surgery
Study NCT00246012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Commercially available dacarbazine will be administered intravenously over a 60-minute period (+30 minutes/-30 minutes) and prior to the intetumumab/placebo infusion. In case participants are unable to tolerate dacarbazine even after 2 dose reductions, they will be given the option to continue on intetumumab alone.
Study NCT03910998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2
Description: Bolus of rocuronium 0.1 mg/kg IV will be given during surgery for a TOF 0/4 and a PTC ≤ 2 (parameters measured every 10 minutes).
Study NCT04047563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline along with standard treatment
Description: PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. In this arm normal saline along with standard treatment will be given for active comparison.
Study NCT04047563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMZ-1620 (sovateltide) along with standard treatment
Description: PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
Study NCT03648879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscope+Cellvizio(R) 100 microscope
Description: Patients will undergo white-light, upper endoscopy. In addition, during this endoscopy patients will undergo Confocal Endoscopic Microscopy (CEM) using the Cellvizio probe (Mauna Kea Technologies) to scan the same anatomic zones.
Study NCT00451152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 30 mg/mL
Description: Administered by anterior juxtascleral depot (AJD) in study eye, either 0.25 mL or 0.5 mL. One injection, 24 months.
Study NCT00451152 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Anecortave Acetate Vehicle
Description: Administered by anterior juxtascleral depot (AJD) in study eye, 0.5 mL. One injection, 24 months.
Study NCT01693367 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SLS (Standard locking screw)
Description: Open reduction and internal fixation (ORIF) of the distal femur with a large fragment locking plate (LISS, LCP)and SLS (Standard locking screw)
Study NCT00246012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered intravenously over a period of 2 hours (+15 minutes/-15 minutes).
Study NCT02205086 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diagnosis
Description: Unaided: The testers will record a differential diagnosis consisting of a list of diseases and their ranking and a prioritized list of test orders, as well as the most appropriate referral for further evaluation and treatment of the patient.~Aided: Then testers will enter the case into diagnostic decision support software and after getting advice from the software, the testers will record the same information as in Unaided, but allowing for the possibility that responses could differ as a result of using the software.
Study NCT01784146 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: For inhalation of oxygen, we used a noninvasive delivery system, semi - closed (Figure 3) consisting of a non-toxic face mask with two unidirectional valves - inspiratory and expiratory branch - connected to the~nebulizer (Airlife Misty Neb, Baxter; Valencia, CA, USA). In the inspiratory branch, a reservoir bag (Hudson RCI, USA) with capacity of 2.5 L was connected, in order to avoid dilution of the gas. This skin was fixed to the patient's face to prevent leakage and to maintain adequate pressurization and improved patient compliance to the PEEP. The nebulizer was fed by a flow of 8 l / min of oxygen.
Study NCT01784146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: For inhalation of oxygen, we used a noninvasive delivery system, semi - closed (Figure 3) consisting of a non-toxic face mask with two unidirectional valves - inspiratory and expiratory branch - connected to the~nebulizer (Airlife Misty Neb, Baxter; Valencia, CA, USA). In the inspiratory branch, a reservoir bag (Hudson RCI, USA) with capacity of 2.5 L was connected, in order to avoid dilution of the gas. This skin was fixed to the patient's face to prevent leakage and to maintain adequate pressurization and improved patient compliance to the PEEP. The nebulizer was fed by a flow of 8 l / min of oxygen.
Study NCT01784146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heliox
Description: For inhalation of heliox, we used a noninvasive delivery system, semi - closed consisting of a non-toxic face mask with two unidirectional valves - inspiratory and expiratory branch - connected to the~nebulizer (Airlife Misty Neb, Baxter; Valencia, CA, USA). In the inspiratory branch, a reservoir bag (Hudson RCI, USA) with capacity of 2.5 L was connected, in order to avoid dilution of the gas. This skin was fixed to the patient's face to prevent leakage and to maintain adequate pressurization and improved patient compliance to the PEEP. The nebulizer was fed by a 11 l / min of heliox for the heliox group in accordance with a protocol of Hess et al.
Study NCT01784146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heliox
Description: For inhalation of heliox, we used a noninvasive delivery system, semi - closed consisting of a non-toxic face mask with two unidirectional valves - inspiratory and expiratory branch - connected to the~nebulizer (Airlife Misty Neb, Baxter; Valencia, CA, USA). In the inspiratory branch, a reservoir bag (Hudson RCI, USA) with capacity of 2.5 L was connected, in order to avoid dilution of the gas. This skin was fixed to the patient's face to prevent leakage and to maintain adequate pressurization and improved patient compliance to the PEEP. The nebulizer was fed by a 11 l / min of heliox for the heliox group in accordance with a protocol of Hess et al.
Study NCT01784146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP
Description: PEEP supplied was 10 cm H2O through valve (Vital Signs,Totowa, USA) attached to the expiratory branch.
Study NCT04364789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TT-00920
Description: Tablets
Study NCT04364789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Tablets
Study NCT00272935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenestin 0.3 mg Tablets
Description: 1 tablet daily
Study NCT00272935 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet daily
Study NCT03496363 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TSH , T4
Description: Thyroid stimulating hormone
Study NCT03176797 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liver MRI
Description: Liver MRI including DWI, IVIM, DKI, T1ρ, T1 mapping of pre-contrast and hepatocyte phase and SWI.
Study NCT02069496 — intervention group
Intervention type: BIOLOGICAL
Intervention: Arepanrix®
Description: Injected according to the prescribing information in the locally approved label by the authorities.
Study NCT00564954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dex-methylphenidate hydrochloride extended-release (Focalin XR)
Description: 20 mg capsule orally once a day for 7 days
Study NCT00564954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally once a day for 7 days
Study NCT03044015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: community based integrated strategy for secondary prevention of OF
Description: Educational programme on pharmacological treatment, diet recommendations, physical activity programme on OF prevention in primary care
Study NCT03044015 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: as usual
Study NCT03532672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Fasting
Description: The volunteers will fast overnight (10 hours) and breakfast will be offered (bread, butter, ham and industrialized fruit juice). The participants will fast for another 10 hours during daily activities.
Study NCT02065622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Study NCT02065622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01919697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plecanatide
Study NCT03346018 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of aqueous humor and plasma samples
Description: The collected samples will be analyzed as follow:~1. Determination of the concentration of various cytokines, chemokines and groeth factors in aqueous humor and in the plasma.~2. Analysis of the mononuclear cells ( T helper lymphocytes CD3+ and CD4+, T cytotoxic lymphocytes CD3+ CD8+, B lymphocytes CD19+, Natural killer lymphocytes CD56+ and CD3- and monocytes CD14+) present in the aqueous humor by cytofluorimetry.~3. Evaluation of the presence of anti-human HSP70 antibodies in plasma samples by Western blot immunoprecipitation assays.~4. Whenever possible (adequate number of cells), in vitro stimulation of mononuclear cells presence in aqueous humor with epitopes from tuberculosis mycobacterium antigens and the analysis of cytokines production in the supernatants.
Study NCT06616662 — intervention group
Intervention type: PROCEDURE
Intervention: MAF
Description: use mucosal advancement flap to treat PAF
Study NCT06616662 — intervention group
Intervention type: PROCEDURE
Intervention: LIFT
Description: use LIFT surgery for treating PAF
Study NCT03123887 — intervention group
Intervention type: OTHER
Intervention: salvage therapy
Description: VDC(L)P regimen or High-dose cytarabine based regimen or High-dose methotrexate based regimen or Hyper-CVAD regimen or FLAG (Flu, Ara-C, G-CSF) ± anthracyclines based regimen or Repeated original induction regimen or VDP or other
Study NCT02696941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500mg once daily and titrated weekly to a dose of 1000mg twice daily for 3 months
Study NCT02696941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: SGLT2 inhibitor has been recommended to be started as part of routine clinical care
Study NCT00670033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost ophthalmic solution (new formulation)